Biography
Biography: Jack A Coleman
Abstract
The Lung Health Institute has been treating chronic lung diseases with regenerative therapy for over four years and has treated over 5,000 patients. The diseases treated are in two broad categories: chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). The common factor in these diseases that the treatment addresses is chronic inflammation. Up to this point these diseases have been treated with symptomatic control only with lung transplant being the only “curative” therapy. By utilizing autologous cells and Platelet Rich Plasma (PRP) the disease progress can be positively affected in the majority of patients treated. The cells and cytokines used will be reviewed as well as proposed mechanisms of action. Protocols utilized for the treatment will be reviewed along with changes that have been made over time. Two studies have been completed and will be summarized. The first is a review study of 568 patients with COPD treated in 2015. Self-reported quality of life measures using the Clinical COPD Questionnaire and pulmonary function tests were measure before treatment and 6 months after. 73% of patients had positively affected quality of life scores and no significant changes were noted in the PFT scores. The second study is a prospective study of 207 patients with COPD (167) or ILD (40). 124 patients completed the 6 month study period. Paired sample T-tests were used for data analysis. 90/124 reported CCQ score unchanged or improved (72.5%), increases of greater or equal to 0.4 (considered significant change for CCQ) was 61/124 (49.2%). We will also discuss need for further testing such as randomized control studies and review potential new therapies to improve treatments for these patients.